Last reviewed 2026-04-20 · How we verify

VXA G1.1 NN-T

Vaxart · Phase 1 active Biologic Quality 0/100

VXA G1.1 NN-T is a Biologic drug developed by Vaxart. It is currently in Phase 1 development.

At a glance

Generic name	VXA G1.1 NN-T
Sponsor	Vaxart
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VXA G1.1 NN-T CI brief — competitive landscape report
VXA G1.1 NN-T updates RSS · CI watch RSS
Vaxart portfolio CI

Frequently asked questions about VXA G1.1 NN-T

What is VXA G1.1 NN-T?

VXA G1.1 NN-T is a Biologic drug developed by Vaxart.

Who makes VXA G1.1 NN-T?

VXA G1.1 NN-T is developed by Vaxart (see full Vaxart pipeline at /company/vaxart).

What development phase is VXA G1.1 NN-T in?

VXA G1.1 NN-T is in Phase 1.

Manufacturer: Vaxart — full pipeline
Compare: VXA G1.1 NN-T vs similar drugs
Pricing: VXA G1.1 NN-T cost, discount & access